Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec departure
confidence 95%
filed 2026-08-07
Item 5.02
Dr. Erica Schwartz, a Class III independent director and Chair of the Clinical Quality Committee, resigned from Aveanna Healthcare's Board of Directors effective immediately on August 5, 2026, due to her nomination and confirmation as Director of the U.S. Centers for Disease Control and Prevention. This is a clear executive departure—the principal disclosed action is a director leaving the board. The resignation of a board chair, particularly one overseeing clinical quality at a healthcare company, is material to investors.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-08-07
Item 5.02
Barry M. Gosin, who has served as CEO since 1979, is stepping down from that role effective December 31, 2026. While the filing also discloses an amended employment agreement keeping him as Chairman of the operating company through 2029, the principal disclosed action is his departure from the CEO position—a material executive departure for a long-tenured leader of a publicly traded company. The amended compensation arrangement is secondary to the departure itself.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-08-07
Item 5.02
Two executive officers resigned effective immediately: Graeme Shaw as Chief Technology Officer and Richard C. Davis as President. The filing explicitly discloses these departures under Item 5.02 and confirms no disagreements with the Company. The departure of a President is material to investors' assessment of the registrant's leadership and operational continuity.
View raw filing on EDGAR →
8-K
Exec departure
confidence 92%
filed 2026-08-07
Item 5.02
Peter Pitsiokos, the Chief Operating Officer, is departing the Company effective October 2, 2026, pursuant to a Separation Agreement executed on August 7, 2026. While the disclosure includes severance terms ($100,000) and cost savings ($620,000 over the liquidation timeline), the principal disclosed action is the departure of a named executive officer. The materiality is reinforced by the fact that only one full-time employee will remain post-termination, indicating significant operational impact during the Company's liquidation phase.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-08-07
Item 5.02
Lisa Roger, the Company's Chief Financial Officer, notified the Company on August 4, 2026 that she would be retiring no later than December 31, 2026. This is a clear departure of a named executive officer (CFO) due to retirement, which is material to investors as it affects the registrant's financial leadership and operational continuity.
View raw filing on EDGAR →
8-K
Exec departure
confidence 92%
filed 2026-08-07
Christine Chambers, Chief Financial Officer, is departing the Company effective August 31, 2026, to pursue new opportunities. The filing explicitly states under Item 5.02 that her separation was not due to disagreement with the Company, board, or management. While the CEO will assume interim financial officer duties, the principal disclosed action is the CFO's departure, making this an exec_departure event. The CFO role is material to investor assessment of the company's financial oversight and governance.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-08-07
The filing discloses the termination of Rick Gonzalez, the Company's Chief Commercial Officer, effective immediately on August 5, 2026. This is a clear executive departure under Item 5.02, as the principal disclosed action is a named officer leaving his role. The CCO position is material to investor assessment of the company's commercial strategy and execution.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-08-07
Robert Brown resigned as a member of the Board of Directors on August 2, 2026. The filing explicitly states his departure was not due to disagreement with the Company, and the Board size is now reduced to four members with three vacancies. This is a clear executive departure event under Item 5.02, material to investors as it affects board composition and governance.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-08-06
Item 5.02
Johnathan L. Wilks resigned as Chief Executive Officer effective August 7, 2026. His unvested equity awards were cancelled as a consequence of his departure from the CEO role, though he was concurrently appointed to the Board.
View raw filing on EDGAR →
8-K
Exec departure
confidence 94%
filed 2026-08-06
Item 5.02
Parag D. Desai, Senior Vice President and Chief Strategy and Digital Officer, is departing the Company effective October 31, 2026, after more than a decade of service. He will transition to part-time status effective August 7, 2026, and cease serving as an executive officer before his final retirement. The filing emphasizes his significant contributions to the Company's strategic direction, technology transformation, and execution of the Footwear First strategy.
View raw filing on EDGAR →
8-K
Exec departure
confidence 85%
filed 2026-08-06
Item 5.02
Joanne M. Maguire retired as a director effective immediately, reducing the Board size from eight to seven members. Thomas J. Manning was appointed to a committee in connection with this change.
View raw filing on EDGAR →
6-K
Exec departure
confidence 95%
filed 2026-08-06
EX-99.1
Alexandre Arnault resigned from his position as Director on the Board of Directors effective August 6, 2026, due to professional commitments. The press release explicitly announces his departure and notes he served for five years during an important chapter of the company's development. This is a clear executive departure requiring disclosure under Item 5.02 of Form 8-K equivalents, and is material given his tenure and the company's acknowledgment of his value to the board.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-08-06
Item 5.02
David Miller's resignation as Co-Chief Executive Officer effective December 31, 2026, is the principal disclosed action. Although the filing also includes the appointment of Justin Betzen as co-President and co-Chief Operating Officer, the Item 5.02 disclosure centers on Miller's departure from the co-CEO role and the resulting succession plan where Vivek Bantwal becomes sole CEO. This is a material executive transition at the principal executive officer level.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-08-06
Item 5.02
David Miller's resignation as Co-Chief Executive Officer and co-principal executive officer, effective December 31, 2026, is the principal disclosed action. While the filing also includes Justin Betzen's appointment as co-President and co-Chief Operating Officer, the central narrative focuses on Miller's departure and the resulting succession plan (Vivek Bantwal becoming sole CEO). This is material to investors as it involves a change in senior executive leadership of the company.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-08-06
Item 5.02
David Miller's resignation as Co-Chief Executive Officer effective December 31, 2026, is the principal disclosed action. While the filing also includes Justin Betzen's appointment as co-President and co-Chief Operating Officer, the departure of a co-CEO is the more material and salient event. Miller's transition to advisory roles and the succession plan (Vivek Bantwal becoming sole CEO) are secondary consequences of the departure.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-08-06
Item 5.02
David Miller's resignation as Co-Chief Executive Officer effective December 31, 2026, is the principal disclosed action. Although the filing also includes Justin Betzen's appointment as co-President and co-Chief Operating Officer, the departure of a co-CEO is the more material event affecting the registrant's leadership structure. The filing explicitly states Miller's resignation and the transition of his duties to Vivek Bantwal, who will become sole CEO.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-08-06
Item 5.02
David Miller's resignation as Co-Chief Executive Officer effective December 31, 2026, is the principal disclosed action. While the filing also includes an appointment (Justin Betzen as co-President and co-COO) and a promotion (Vivek Bantwal becoming sole CEO), the opening and most substantive disclosure concerns Miller's departure from the co-CEO role. The departure of a co-principal executive officer is material to investors assessing leadership continuity.
View raw filing on EDGAR →
8-K
Exec departure
confidence 92%
filed 2026-08-06
Item 5.02
Dr. Barbara Weber's employment as Executive Chair ended on August 3, 2026, and she resigned from all officer and board member positions. While the disclosure includes severance and compensation details, the principal disclosed action is her departure from the company and board. The filing emphasizes the termination of employment and resignation from all positions, making this fundamentally an executive departure event.
View raw filing on EDGAR →
6-K
Exec departure
confidence 92%
filed 2026-08-06
Ricardo Chagas has resigned from his positions as Chief Executive Officer and Chief Financial Officer of Ambipar Response, effective immediately. While the announcement also mentions the appointment of Dennys Spencer as Interim CEO and CFO, the principal disclosed action is the departure of the CEO/CFO, making this an executive departure event. The simultaneous appointment is secondary to the resignation announcement.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-08-06
The filing discloses that Larry Ellis resigned as a member of the Board of Directors on July 31, 2026, with explicit statement that the resignation was not due to disagreement. While the filing also mentions board compensation approval on August 1, 2026, the principal disclosed event is the director departure. The resignation of a board member is material to investors' assessment of governance and board composition.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-08-06
Item 5.02
The filing discloses two departures: Erick Soto's resignation as Chief Product Officer (effective August 5, 2026) and Kunal Mehta's resignation as a director and committee member (effective August 7, 2026). While the filing also mentions appointments of Ram Menghani and Michael Koehneman to committees, the principal disclosed actions center on the departures of named executives and a director. The departure of a CPO and board member are material events affecting the registrant's leadership structure.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-08-06
Item 5.02
Steve Pantelick, Chief Financial Officer, announced his planned retirement effective into Q1 2027, with a transition period as senior adviser through July 1, 2027.
View raw filing on EDGAR →
8-K
Exec departure
confidence 98%
filed 2026-08-06
Item 5.02
Shannon Kinney, serving as Executive Vice President, Chief Administrative Officer, General Counsel, and Corporate Secretary, notified the Company on August 2, 2026 of her resignation effective August 31, 2026. This is a clear departure of a senior officer holding multiple critical roles (legal, compliance, and corporate governance functions). The departure of a C-suite executive with broad responsibilities is material to investors.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-08-06
Andrew Schaap notified the Board of his intention to resign as a director effective July 31, 2026. This is a clear director departure disclosed under Item 5.02(b). The filing explicitly states the resignation was not due to any dispute or disagreement, indicating an orderly transition. Director departures are material events affecting the composition of the board and governance structure.
View raw filing on EDGAR →
8-K
Exec departure
confidence 85%
filed 2026-08-06
Item 5.02
The principal disclosed action is the departure of Sheri Savage as Chief Financial Officer effective August 5, 2026, following her notification of intention to retire. Although the filing also mentions Michael Keogh's appointment as her successor (previously disclosed), the focus of this Item 5.02 disclosure is Savage's cessation of officer duties and the terms of her transition agreement, including her continued employment as a non-officer Finance Advisor through May 1, 2027. The departure is material as it involves a named executive officer in a critical financial role.
View raw filing on EDGAR →
8-K
Exec departure
confidence 72%
filed 2026-08-06
Item 5.02
Robert You resigned as President and Chief Financial Officer effective July 31, 2026, with no disagreement cited. While the filing also discloses Vikas Mittal's appointment as Interim CFO, the primary disclosed action centers on You's departure from a named executive officer role. The appointment is secondary and interim in nature, making the departure the more salient event.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-08-05
Item 5.02
Courtney Nelson Wills, Senior Vice President, General Counsel and Corporate Secretary, notified MiniMed of her resignation effective September 25, 2026. The disclosure centers on her departure from a senior officer role responsible for legal, governance, and compliance functions. While the company notes the departure is for personal reasons and not due to disagreement, the loss of a General Counsel is material to investors' assessment of the company's governance and legal oversight.
View raw filing on EDGAR →
8-K
Exec departure
confidence 92%
filed 2026-08-05
Item 5.02
Srini Tallapragada is stepping down from his role as President and Chief Engineering and Customer Success Officer, a named executive officer position at Salesforce. Although he transitions to a Special Advisor role through August 2027, the principal disclosed action is his departure from a senior executive position effective August 6, 2026. The transition agreement details (salary reduction to $75,000/year, continued equity vesting, and release of claims) are ancillary to the core departure event.
View raw filing on EDGAR →
6-K
Exec departure
confidence 95%
filed 2026-08-05
The filing discloses the resignations of three named executives: Tiffany See (Chief Human Resources Officer, effective June 19, 2026), Frank Jeng (Chief Legal Officer interim, effective July 31, 2026), and Dmitri Hu (Chief Financial Officer, effective August 14, 2026). These are material departures of senior officers during judicial management proceedings, affecting the registrant's leadership structure and governance.
View raw filing on EDGAR →
8-K
Exec departure
confidence 72%
filed 2026-08-05
Item 5.02
Robert Kalebaugh, VP of Sales, retired from his position effective July 31, 2026. In connection with his departure, the company entered into an amended employment agreement and consulting agreement with equity awards.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-08-05
Item 5.02
CFO Saurabh Sinha informed the Company on July 30, 2026 of his plan to resign effective September 5, 2026, after six years of service. Rupesh Maheshwari was appointed as interim CFO to ensure continuity of financial leadership.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-08-05
Item 5.02
Kirsten Newquist, the Chief Executive Officer and Board member, notified the Board on July 30, 2026 of her intention to resign from both positions following the closing of the pending Asset Sale. While the effective date has not yet been determined, the disclosure centers on the principal action of a named executive departing her role. The departure of a CEO is material to investors assessing the registrant's leadership and governance.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-08-05
Item 5.02
Simon Lowry, Chief Medical Officer and Head of Research and Development, departed the company effective August 19, 2026, as his role was eliminated as part of the organizational restructuring.
View raw filing on EDGAR →
8-K
Exec departure
confidence 92%
filed 2026-08-05
Item 5.02
Albert J. Miralles, Chief Financial Officer and Executive Vice President, announced his intention to retire in 2027 following an orderly transition period. The announcement includes compensatory arrangements for the transition, with Miralles to serve as Executive Advisor at a reduced salary of $60,000 with no incentive awards post-March 2027.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-08-05
Norman Newton resigned from the Board of Directors and from the Audit Committee and Nomination Committee on August 4, 2026. The filing explicitly discloses under Item 5.02 that this departure was not due to disagreement with the Company, but the resignation of a board member and committee member is a material governance event affecting the composition of the board and its oversight committees.
View raw filing on EDGAR →
8-K
Exec departure
confidence 94%
filed 2026-08-05
Item 5.02
James Benson, Executive Vice President and Chief Financial Officer, notified the Company on July 31, 2026 that he will resign from his position by March 31, 2027 in connection with his planned retirement. The company has initiated a CFO search, and Benson will oversee the transition.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-08-05
Item 5.02
Matthew Newcomb resigned as Chief Financial Officer effective August 7, 2026. Mark Troughton was appointed as interim CFO, and Newcomb received a transition agreement and severance terms.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-08-05
Item 5.02
Ehsan Ehsani resigned from his position as Chief Investment Officer of Legato Merger Corp. IV on July 31, 2026. The disclosure centers on the departure of a named officer from the Company, with explicit statement that the resignation was for personal reasons and not due to disagreement. This is a clear executive departure event material to investors in a SPAC context where the CIO role is significant.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-08-05
Item 5.02
Robert Rico, the Chief Accounting Officer and principal accounting officer, has notified the Company of his intention to resign effective September 30, 2026. The principal disclosed action is a named executive officer departing his role. While the resignation is stated to be amicable and not due to disagreements, the departure of the principal accounting officer is material to investors as it affects the registrant's financial reporting oversight and internal controls.
View raw filing on EDGAR →
6-K
Exec departure
confidence 95%
filed 2026-08-05
Mr. Poh Chit Wen, Chief Financial Officer of GrowHub Limited, tendered his resignation effective upon mutual agreement. The departure of a CFO is a material executive change that would affect a reasonable investor's assessment of the company's financial leadership and governance. The filing explicitly states the resignation was due to personal reasons with no disagreement on company matters.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-08-04
Item 5.02
Joseph C. Bartolacci, President and Chief Executive Officer of Matthews International Corporation, announced his retirement effective at the Retirement Date after 29 years with the company and 20 years as CEO. The Board has initiated a succession process to identify his replacement.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-08-04
Item 5.02
Jennifer Taubert, Executive Vice President and Worldwide Chairman of Innovative Medicine (a $60+ billion business unit) and Executive Committee member, is retiring effective September 1, 2026. While the filing also discloses Tom Cavanaugh's appointment as her successor, the principal disclosed action centers on Taubert's departure from a senior executive role after 21 years. The appointment is presented as a succession event, making the departure the salient event.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-08-04
Item 5.02
Heather H. Teilhet, the current Executive Vice President, External Affairs, has informed the company that she will resign from her position effective January 1, 2027, due to her appointment as President/CEO of Georgia Electric Membership Corporation. While the disclosure mentions both her departure and the external appointment, the principal action disclosed to investors is her resignation from the registrant, making this a departure event. The departure of a senior executive is material to investors' assessment of the company.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-08-04
Item 5.02
Leif E. Pedersen departed his role as President and Chief Commercial Officer effective August 1, 2026. While the disclosure mentions his transition to a Senior Advisor role and subsequent severance benefits, the principal disclosed action is the departure of a named executive officer from a senior leadership position. This is material to investors as it affects the company's executive leadership structure and operational continuity.
View raw filing on EDGAR →
6-K
Exec departure
confidence 95%
filed 2026-08-04
EX-99.1
Bryan Cunningham, President of Liberty Defense, departed the Company effective July 22, 2026, to return to privacy and advocacy work. This is a clear executive departure of a named officer. The Company's CEO Bill Frain acknowledged the departure and stated the position will not be immediately filled, indicating the departure is material to the organization's leadership structure.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-08-04
Item 5.02
Dr. Kristen K. Buck, Executive Vice President of R&D and Chief Medical Officer, was terminated effective August 3, 2026 in connection with the Board-approved workforce reduction, triggering contractual severance obligations including 12 months base salary and target bonus plus COBRA.
View raw filing on EDGAR →
8-K
Exec departure
confidence 85%
filed 2026-08-04
Item 5.02
Seven directors—Kofi Bruce, Rachel A. Gonzalez, Jeffrey T. Huber, Talbott Roche, Richard A. Simonson, Luis Ubiñas, and Heidi Ueberroth—voluntarily resigned from the board and all committees effective at the closing of the acquisition on August 4, 2026.
View raw filing on EDGAR →
8-K
Exec departure
confidence 92%
filed 2026-08-04
Item 5.02
Matthew Pasch, Executive Vice President and Chief Human Resources Officer, is departing effective September 1, 2026. The disclosure includes severance and equity vesting details related to his departure.
View raw filing on EDGAR →
8-K
Exec departure
confidence 94%
filed 2026-08-04
Item 5.02
Dr. Jeffrey A. Graves, the Company's President and Chief Executive Officer and Board member, is departing the Company and retiring from the Board effective upon hiring a successor. The filing discloses severance and consulting arrangements in connection with his departure.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-08-04
Item 5.02
J. Patrick O'Keefe, Vice President and Senior Vice President of Universal Ingredients, Inc., notified the Company on July 29, 2026 of his intention to retire. The disclosure centers on the departure of a named executive officer, with the Company actively searching for a successor. This is a clear executive departure event material to investors assessing leadership continuity.
View raw filing on EDGAR →